IP Library Granted Patent US 10,450,564
Granted Patent B2
US 10,450,564 · App. 15/705,739 · Granted Oct 22, 2019

Micromirs

Inventors: Susanna Obad (Malmo, SE); Sakari Kauppinen (Smorum, DK); Joacim Elmen (Malmo, SE); Morten Lindow (Copenhagen SV, DK); Markus Heidenblad (Lund, SE)
Assignee: Roche Innovation Center Copenhagen A/S
C12N15/113A61K31/713A61K45/06C12N15/111C12N15/1131C12N2310/113C12N2310/14C12N2310/141C12N2310/315C12N2310/32C12N2310/321C12N2310/322C12N2310/3231C12N2310/3341C12N2310/34C12N2310/351C12N2310/3513C12N2310/3525C12N2310/3533C12N2320/31Y02A50/465
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,450,564
App. No.
15/705,739
Granted
Oct 22, 2019
Kind
B2
Abstract

The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.

Claims (18)

1. A method for de-repression of a mRNA in a cell, wherein the expression of the mRNA is repressed by a miRNA in said cell, the method comprising administering an effective amount of an oligomer to said cell, to de-repress the expression of the mRNA, wherein the oligomer has a length of 7, 8, 9 or 10 nucleotide units which are fully complementary to said miRNA, wherein each nucleotide unit is an LNA nucleotide unit, and wherein at least 75% of the internucleoside linkages between the LNA nucleoside units are phosphorothioate internucleoside linkages, and wherein the contiguous nucleotide sequence of the oligomer is complementary to the seed sequence of said microRNA.

2. The method according to claim 1 , wherein all of the internucleoside linkages between the LNA nucleoside units are phosphorothioate internucleoside linkages.

3. The method according to claim 1 , wherein the oligomer is 7 LNA nucleotides in length.

4. The method according to claim 1 , wherein the oligomer is 8 LNA nucleotides in length.

5. The method according to claim 1 , wherein the oligomer is 9 LNA nucleotides in length.

6. The method according to claim 1 , wherein the oligomer is 10 LNA nucleotides in length.

7. The method according to claim 2 , wherein the oligomer is 7 LNA nucleotides in length.

8. The method according to claim 2 , wherein the oligomer is 8 LNA nucleotides in length.

9. The method according to claim 2 , wherein the oligomer is 9 LNA nucleotides in length.

10. The method according to claim 2 , wherein the oligomer is 10 LNA nucleotides in length.

11. The method according to claim 1 , wherein nucleotides 1-6 as measured from the 2′ end of the oligomer are fully complementary to the microRNA seed region.

12. The method according to claim 1 , wherein nucleotides 1-7 as measured from the 2′ end of the oligomer are fully complementary to the microRNA seed region.

13. The method according to claim 1 , wherein nucleotides 2-7 as measured from the 2′ end of the oligomer are fully complementary to the microRNA seed region.

14. The method according to claim 2 , wherein nucleotides 1-6 as measured from the 2′ end of the oligomer are fully complementary to the microRNA seed region.

15. The method according to claim 2 , wherein nucleotides 1-7 as measured from the 2′ end of the oligomer are fully complementary to the microRNA seed region.

16. The method according to claim 2 , wherein nucleotides 2-7 as measured from the 2′ end of the oligomer are fully complementary to the microRNA seed region.

17. The method according to claim 1 , wherein the microRNA is a mammalian or viral microRNA, and the cell is a mammalian cell.

18. The method according to claim 1 , wherein the microRNA is a human microRNA, and the cell is a human cell.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: ROCHE INNOVATION CENTER COPENHAGEN A/S
To: RICC A/S
Reel/Frame 073892/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: OBAD, SUSANNA; KAUPPINEN, SAKARI; ELMEN, JOACIM; LINDOW, MORTEN
To: SANTARIS PHARMA A/S
Reel/Frame 048654/0694 →
CHANGE OF NAME Recorded Mar 20, 2019
From: SANTARIS PHARMA A/S
To: ROCHE INNOVATION CENTER COPENHAGEN A/S
Reel/Frame 048654/0746 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: HEIDENBLAD, MARKUS
To: SANTARIS PHARMA A/S
Reel/Frame 048654/0894 →